Oil Surges, Treasury Yields Climb a Fifth Day, Software Retreats: Stock Market Today
The 10-year Treasury yield hit a 19-month high and crude jumped above $88 as traders lifted Fed rate-hike odds to 68%, cracking high-multiple software stocks.
Stocks · News reference
Moderna Advances Ebola Vaccine Into Human Testing
Moderna starts Phase 1 trials for Ebola vaccine mRNA-1469. See premarket MRNA stock reaction, analyst updates, and ETF exposure.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Next Biotech Boom May Be Cancer Vaccines: Watch These ETFs
Moderna’s cancer vaccine breakthrough puts biotech, mRNA and genomics ETFs in focus. Here are the funds worth watching.
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?
The article provides an in-depth analysis of the iShares Biotechnology ETF (IBB), a smart beta ETF with over $10.5 billion in assets that tracks the Nasdaq Biotechnology Index. With a 0.44% expense ratio and 252 holdings, IBB offers diversified exposure to biotechnology and pharmaceutical companies, though it carries higher risk with a beta of 0.70 and 20.59% standard deviation. The ETF returned 23.89% year-to-date and 51.48% over the past year as of August 2026, with top holdings including Amgen, Vertex Pharmaceuticals, and Gilead Sciences.
Nasdaq 100 Falls As Warsh Revives Rate Hike Bets: Stock Market Today
Fed Chair Kevin Warsh said underlying inflation has not improved, pushing September hike odds to 60%, lifting the 2-year yield
BioNTech vs. Moderna: Which Is the Better Cancer Vaccine Stock to Buy Now?
BioNTech and Moderna, both mRNA vaccine pioneers during the pandemic, are now pivoting to cancer vaccines as COVID revenue declines. Moderna is favored due to stronger recent clinical progress, including positive phase 3 results for its personalized cancer vaccine intismeran autogene and FDA approval for mFLUSIVA flu vaccine. While BioNTech has a deep pipeline including pumitamig, it has yet to deliver comparable phase 3 wins. Moderna's $61.2 billion market cap reflects investor confidence in its near-term commercialization prospects versus BioNTech's $26 billion valuation.
Does Moderna's mRNA Flu Shot Face a New Challenge From GSK?
Moderna secured FDA approval for mFlusiva, the first mRNA-based seasonal flu vaccine, establishing a foothold in the multibillion-dollar flu vaccine market. However, GSK announced plans to advance its own mRNA flu vaccine into phase III trials, which targets two viral proteins (HA and NA) and showed superior immune responses in phase II studies. While GSK's vaccine is still years away from market approval, it could pose a competitive challenge to Moderna's mFlusiva, which currently targets only HA like traditional flu vaccines.